Clinical trials | EDC - IRCCS - Istituto Nazionale dei Tumori

INFO & CONTACTS: +39 02 2390 1

Search

Search

Follow us on

Clinical trials

A Phase II, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Volrustomig Priming Regimens in Combination with Other Anticancer Agents in Participants with

Phase: Phase II-III clinical trials

Main Facility: Thoracic Oncology Unit

Drug: Volrustomig
Chemotherapy (Carboplatin an Pemetrexed)
A Phase II study evaluating efficacy of KTE-X19 CAR-T cell therapy in Relapsed or Refractory Mantle-Cell Lymphoma achieving a partial response during Ibrutinib salvage therapy

Phase: Phase II-III clinical trials

Principal Investigator: Prof. Corradini Paolo

Main Facility: Ematologia

Drug: KTE-X-19 (brexucabtagene autoleucel)
A phase Ib/II, open-label, multicentric study evaluating the Safety, Activity, and Pharmacokinetics of Divarasib in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metas

Phase: Phase II-III clinical trials

Principal Investigator: Prof. De Braud Filippo

Main Facility: Thoracic Oncology Unit

Drug: Divarasib, Pembrolizumab, Chemotherapy
A phase I/II b (randomized controlled) study of atezolizumab combined to BEGEV regimen as first salvage treatment in patients with relapsed or refractory Hodgkin’s lymphoma candidate to autologous stem–cell transplantati

Phase: Phase II-III clinical trials

Principal Investigator: Prof. Corradini Paolo

Main Facility: Ematologia

Drug: Atezolizumab
A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination with Pembrolizumab (MK-3475) Versus Treatment of Physician’s Choice (TPC) in Participants With Triple-Negativ

Phase: Phase II-III clinical trials

Main Facility: Oncologia Medica 1

Drug: MK-2870
A phase 3, randomized, open-label study to evaluate the efficacy and safety of petosemtamab in combination with pembrolizumab versus pembrolizumab alone as first-line treatment for PD-L1 positive recurrent or metastatic

Phase: Phase II-III clinical trials

Main Facility: Oncologia Medica 3 - Tumori testa-collo

Drug: MCLA-158-CL03
A Phase 3, Randomized, Multi-center, Open-label Study of DB-1303 Versus Investigator’s Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low, Hormone Receptor Positive (HR+) Metastatic Breast Cancer

Phase: Phase II-III clinical trials

Main Facility: Oncologia Medica 1

Drug: DB-1303
Capecitabina, Paclitaxel, Nab-Paclitaxel
A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator- Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With Resected Stag

Phase: Phase II-III clinical trials

Main Facility: Thoracic Oncology Unit

Drug: Pembrolizumab
V940 (mRNA-4157)/ Placebo
A Phase 3, Randomized, Double-blind, Multicenter Study of MK-1084 in Combination With Pembrolizumab Compared With Pembrolizumab Plus Placebo as Firstline Treatment of Participants With KRAS G12C-Mutant, Metastatic NSCLC

Phase: Phase II-III clinical trials

Main Facility: Thoracic Oncology Unit

Drug: MK-1084 Pembrolizumab
A phase 3, open-label, randomized, controlled study to evaluate the efficacy and safety of MCLA-158-CL02 versus investigator’s choice of monotherapy in patients previously treated for incurable, metastatic, or recurrent

Phase: Phase II-III clinical trials

Main Facility: Oncologia Medica 3 - Tumori testa-collo

Drug: MCLA-158-CL02
A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab

Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV o

Phase: Phase II-III clinical trials

Main Facility: Thoracic Oncology Unit

Drug: Sotorasib, Pembrolizumab, Carboplatino, Pemetrexed
A Phase 3 Study of Pembrolizumab in Combination With Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) followed by Pembrolizumab With or Without Maintenance MK-2870 in the First-line Treatment of Metastatic Squamous Non-

Phase: Phase II-III clinical trials

Main Facility: Thoracic Oncology Unit

Drug: MK2870 (sacituzumab tirumotecan)
Pembrolizumab
Chemotherapy
A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301)

Phase: Phase II-III clinical trials

Main Facility: Oncologia Medica 1 - Unità Oncologia Medica Melanomi

Drug: Brenetafusp, Nivolumab
A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB (N2) NSCLC not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinu

Phase: Phase II-III clinical trials

Main Facility: Thoracic Oncology Unit

Drug: Pembrolizumab
MK-2870 (sacituzumab tirumotecan)
Chemotherapy
A Phase 3 open-label, randomized, active-controlled, multicenter trial to evaluate the efficacy and safety of orally administered BAY 2927088 compared with standard of care as a first-line therapy in patients with locall

Phase: Phase II-III clinical trials

Main Facility: Thoracic Oncology Unit

Drug: Pembrolizumab
BAY 2927088
(Carboplatin or cisplatin + pemetrexed)
A Phase 2/3, Randomized, Double-Blind, Controlled Study of XL092 in Combination With Pembrolizumab vs Pembrolizumab in the First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamo

Phase: Phase II-III clinical trials

Main Facility: Oncologia Medica 3 - Tumori testa-collo

Drug: XL092
A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non--Small Cell Lung Cancer

Phase: Phase II-III clinical trials

Main Facility: Thoracic Oncology Unit

Drug: Adagrasib
Pembrolizumab
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearra

Phase: Phase I-II clinical trials

Main Facility: Thoracic Oncology Unit

Drug: Repotrectinib
A multicentre, Phase II, single-arm, interventional study of neoadjuvant durvalumab and platinum-based chemotherapy (CT), followed by either surgery and adjuvant durvalumab or chemoradiotherapy (CRT) and consolidation du

Phase: Phase II-III clinical trials

Main Facility: Thoracic Oncology Unit

Drug: Durvalumab (a type of anti-cancer drug called immunotherapy).
Standard chemotherapy treatment (SoC): pemetrexed/cisplatin or pemetrexed/carboplatin.
If the tumour is unresectable, it will receive SoC radiotherapy.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of AV-299 in Combination with Cetuximab in Participants with Recurrent or Metastatic (R/M) HPV-Negative Head and Neck Squamous Cell Carcinoma

Phase: Phase II-III clinical trials

Main Facility: Oncologia Medica 3 - Tumori testa-collo

Drug: AV-299